Dupilumab an alternative for children with severe AD
19 May 2021
byAudrey Abella
The addition of the monoclonal antibody dupilumab to a standard topical corticosteroid (TCS) regimen led to significant improvements in scoring AD (SCORAD*) and its components, as well as EASI** scores, in children with severe atopic dermatitis (AD), according to data from the phase III LIBERTY AD PEDS trial presented at PAS 2021.
